Article

A Novel Molecular Target in EGFR-Mutant Non-Small Cell Lung Cancer Treated With a Combination of Osimertinib and Pemetrexed

2021-03-11

Abstract excerpt

Overcoming acquired resistance to the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib is currently an important clinical issue in treating EGFR-mutant non-small cell lung cancer (NSCLC) patients. EGFR-TKI may synergize with chemotherapy and offer novel treatment strategies for overcoming acquired resistance. Here, we evaluate the therapeutic potential of combining osimertinib with...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4d58e05c-57ea-5595-b00b-e0aa76a05ef1
DOI: 10.21203/rs.3.rs-257308/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Novel Molecular Target in EGFR-Mutant Non-Small Cell Lung Cancer Treated With a Combination of Osimertinib and PemetrexedDOI 10.21203/rs.3.rs-257308/v1Read

A Novel Molecular Target in EGFR-mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed.Semantic proximity Read

The effect of PLK1 inhibitor in osimertinib resistant non-small cell lung carcinoma cells.Semantic proximity Read

ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.Semantic proximity Read

New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer.Semantic proximity Read

Strategies of overcoming osimertinib resistance in EGFR-mutated non-small cell lung cancer.Semantic proximity Read

3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinibSemantic proximity Read

Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer.Semantic proximity Read

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation.Semantic proximity Read

PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer.Semantic proximity Read

MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers.Semantic proximity Read

Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).Semantic proximity Read

The combination of osimertinib with Raf inhibitor overcomes osimertinib resistance induced by KRAS amplification in EGFR-mutated lung cancer cells.Semantic proximity Read